HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

DXP-604

Also Known As:

DXP604

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Neutralizing Antibodies: 9981
        DXP-604: 1
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Neutralizing Antibodies: 9981
        DXP-604: 1
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Neutralizing Antibodies: 9981
        DXP-604: 1

Related Diseases

1.

01/01/2023 - "Preliminary results showed that DXP-604 can accelerate recovery from Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 Delta variant in hospitalized patients with mild to moderate clinical symptoms. "
01/01/2023 - "The ongoing clinical trials of DXP-604 neutralizing antibody will clarify its utility as a new attractive countermeasure for high-risk COVID-19."
01/01/2023 - "Clinical observation of neutralizing antibody DXP-604 for treatment critical COVID-19 patients infected with SARS-CoV-2 Delta variant."

Related Drugs and Biologics

1.	Neutralizing Antibodies